Quoin Pharmaceuticals, Ltd.

Clinical/early-stage biotech — rare-disease (dermatology) clinical micro-cap, funded.

Strengths

• Liquidity — current ratio 3.6 (48th)

Risks

• Pre-revenue, deep losses — per metrics
• Pre-revenue/clinical-stage — history of losses & need for capital per risk factors
• Binary clinical & funding risk — per 10-K

Notable findings

• Going concernBased on our current business plans and cash, cash equivalents and investments on hand, management has concluded that there is substantial doubt about our ability to continue as a going concern for a
• Buying back stockNet buyback — share count -86%/yr over 3y
• Notable holderHeld by 1 notable fund(s): CITADEL ADVISORS LLC (as of 2026-03-31)